You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
A Lund University-led team developed two methylation risk scores to predict which patients would or would not respond to treatment and experience side effects.
In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.
A new analysis highlighted a decrease in the abundance of butyrate-producing bacteria among individuals with prediabetes or type 2 diabetes.
A Regeneron-led team identified four variants that affect LDL cholesterol levels and are much more prevalent among Southwestern American Indians.
Researchers found that diurnal gut microbe fluctuations are disrupted in individuals with type 2 diabetes, leading to a bacterial signature for risk profiling.
Phenotypic clustering identified distinct forms of PCOS with specific gene variants, providing a promising strategy for enhancing the treatment of this syndrome.
A meta-analysis including 1.4 million people from five ancestral groups identified 318 novel variants associated with type 2 diabetes and related vascular outcomes.
KidneyIntelX can be used to report risk assessment results for fast-progressing kidney disease and future kidney failure for patients with chronic kidney disease.
The researchers said the findings underscore the need to study disease variants in a range of ancestral backgrounds.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.